Lupvindol Biosciences is a dynamic, cutting-edge company with robust intellectual property (IP) for combining the benefits of two existing FDA-approved pharmaceutical drugs— corticosteroids and CBD—into a fixed-dose combination formulation. This innovation aims to replace traditional inflammatory and auto immune regimens plagued by dose-limiting side effects, especially with prolonged use. Our data suggest enhanced efficacy and safety compared to steroids alone, at much lower doses.

The Problem
Maximizing Steroid Benefits While Minimizing Side Effects
Corticosteroids are powerful tools in managing inflammatory pain and autoimmune conditions but come with a significant risk of side effects, particularly with long-term or high-dose use. These side effects can include osteoporosis, muscle atrophy, high blood pressure, diabetes, or psychiatric disturbances such as mood swings or psychosis. Physical changes like “moon face,” fat redistribution, or skin thinning are also common, alongside vision problems such as cataracts or glaucoma.
The Solutions
Patent Combination Therapy
Lupvindol’s robust patent portfolio underpins the development of formulations combining CBD and corticosteroids in optimized ratios. CBD’s established potential as a steroid-sparing agent allows Lupvindol to address the adverse effects associated with long-term or high-dose steroid use, offering a safer alternative for managing inflammatory and autoimmune conditions.

Therapeutics

Health & Wellness

Lupvindol Biosciences Limited

Org chart

Teams

Offices